The Union Health Ministry has banned the manufacture, sale, and distribution of 16 fixed-dose combination (FDC) drugs in India with immediate effect. The Department of Health cited a lack of therapeutic justification and potential risks to patients, acting on recommendations from the Drugs Technical Advisory Board (DTAB) following a multi-year regulatory review.
Why did the Health Ministry ban these 16 drug combinations?
The ban stems from findings that several common drug combinations lacked scientific evidence to support their use. According to the Department of Health, the combinations were “irrational,” meaning the drugs paired together didn’t provide a proven clinical benefit over using the ingredients separately.
An expert panel examining these drugs found that certain pairings were “pharmacodynamically irrelevant.” For example, the committee noted that combining amoxicillin, an antibiotic, with serratiopeptidase, an enzyme used to reduce swelling, lacked sound clinical evidence. The panel stated these combinations did not follow standard therapeutic guidelines.
In other cases, the Ministry identified redundant ingredients. The committee noted that dicyclomine, used for intestinal pain, already possesses potent anti-cholinergic properties. Therefore, adding another anti-cholinergic agent like clidinium bromide was deemed unjustified.
A Fixed-Dose Combination (FDC) is a single medication—such as a tablet or capsule—that contains two or more active pharmaceutical ingredients. While they can improve patient compliance, they must be backed by rigorous pharmacokinetic data to ensure safety.
Which specific medications are included in the ban?
The prohibited list covers a wide range of treatments, including antibiotics, painkillers, diabetes management drugs, and topical skin products. The ban is imposed under Section 26A of the Drugs and Cosmetics Act, 1940.
Antibiotics and Pain Relief
The banned list includes several antibiotic-enzyme combinations often used for bacterial infections, such as:
- Amoxicillin + serratiopeptidase
- Amoxicillin + serratiopeptidase + lactobacillus sporogenes
- Amoxicillin + cloxacillin + lactic acid bacillus + serratiopeptidase
- Cefuroxime + serratiopeptidase
- Cefadroxil + probenecid
The committee specifically flagged the cefadroxil + probenecid combination because there was no pharmacokinetic data to justify the addition of probenecid for dose titration.
Pain and gastrointestinal combinations also face the ban, including:
- Dicyclomine + paracetamol + clidinium bromide + chlordiazepoxide
- Dicyclomine + paracetamol + clidinium bromide
- Paracetamol + lignocaine
- Acetyl salicylic acid + ethoheptazine
Diabetes and Topical Formulations
For patients managing Type 2 diabetes, the combination of gliclazide + chromium picolinate is now prohibited. The committee stated that neither national nor international standard treatment guidelines recommend using chromium picolinate for this purpose.
Several aloe-based topical products were also removed from the market. The committee found these formulations were “not defined as well as characterised” and lacked sufficient scientific support. Banned topical combinations include:
- Aloe vera + jojoba oil + wheat germ oil + tea tree oil
- Aloe extract + allantoin + alpha-tocopheryl acetate + D-Penthenol + vitamin A
- Aloe extract + vitamin E + dimethicone + glycerine
- Aloe vera + jojoba oil + vitamin E
- Aloe vera + orange oil
- Aloe vera + vitamin E + herbal
How did the regulatory investigation unfold?
This decision follows a prolonged review process that began with an expert panel examining FDCs in 2021. The panel found that peer-reviewed scientific evidence did not support the rationality of many existing combinations.
The Drugs Technical Advisory Board (DTAB), which serves as the apex statutory body advising the government on drug policy, reviewed these findings. The DTAB’s sub-committee was tasked with examining all irrational FDCs in detail. Before finalizing their report on December 28, 2024, the sub-committee provided manufacturers and stakeholders an opportunity to submit data through public notices.
Following the sub-committee’s recommendation, the Central Government concluded that a ban was necessary and expedient in the larger public interest.
If you are currently taking any of these combinations, do not stop your medication abruptly. Consult your healthcare provider immediately to discuss safe, single-ingredient alternatives that follow standard therapeutic guidelines.
Frequently Asked Questions (FAQ)
What is a fixed-dose combination (FDC)?
An FDC is a single medicine that combines two or more active drugs into one dosage form, like a tablet or capsule.
Is the ban on these 16 drugs immediate?
Yes. The Union Health Ministry notified that the ban on the manufacture, sale, and distribution of these drugs takes effect immediately.
Why were aloe-based products included in the ban?
The expert committee found that these specific topical formulations were not adequately defined or characterised and lacked the necessary scientific support.
What is the legal basis for this ban?
The ban was imposed under Section 26A of the Drugs and Cosmetics Act, 1940.
Stay informed on the latest healthcare regulatory updates. Have questions about how these changes affect your prescriptions? Leave a comment below or subscribe to our newsletter for more expert analysis.
